Regulatory Roundup: FDA Posts PDUFA Meeting Minutes

The new United Kingdom-based firm has sites located in France, Spain, and Sweden, thanks to an acquisition of Synerlab Group and several Recipharm facilities in 2024.

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Vitrakvi (larotrectinib) was first granted accelerated approval by FDA in November 2018.

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.

The company has plans to invest $23 billion during the next five years to expand manufacturing and R&D in the US, which will include seven new facilities.

Siemens said spending on AI software is predicted to double by the end of the 2020s, in a market increasingly driven by structural shifts that underscore a need for digital transformation.